828
Views
15
CrossRef citations to date
0
Altmetric
Drug Evaluation

Colesevelam hydrochloride: a specifically engineered bile acid sequestrant

, MD, PhD & , MD
Pages 237-255 | Published online: 18 Jan 2017
 

Abstract

There is a well established association between serum cholesterol and coronary heart disease and this relationship has been found to be related to concentration and is continuous over the entire distribution of cholesterol levels. Recent studies have shown that intensive lipid lowering is beneficial and more stringent guidelines are advocated to improve the clinical outcome. Although statins are the first-line agents for the treatment of hypercholesterolemia, often it is evident that combination therapy is required to achieve the desired reduction in LDL-cholesterol (LDL-C). Niacin and bile acid sequestrants were among the first lipid-lowering drugs developed to lower LDL-C and have been established to be effective in both monotherapy and combination therapy. However, tolerability and compliance issues have limited the use of the traditional bile acid sequestrants. Colesevelam hydrochloride is the newest bile acid sequestrant and shows reduced adverse effects, improved tolerance and better compliance.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.